1. Home
  2. BLRX
  3. BLRX News

Latest BioLineRx Ltd. (BLRX) News on May 15, 2025

BLRX

Zacks Small Cap Research

a month ago

BLRX: 2024 Financial Results

BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...
BLRX

GuruFocus.com

a month ago

BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...

BioLineRx Reports 2024 Financial Results and Provides Corporate Update
BLRX

PR Newswire

a month ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report 2024 Annual Results on March 31, 2025
BLRX

PR Newswire

2 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

BLRX: Aphexda Transition Progressing
BLRX

Zacks Small Cap Research

3 months ago

BLRX: Aphexda Transition Progressing

BioLineRx Issues Letter to Shareholders
BLRX

PR Newswire

4 months ago

BioLineRx Issues Letter to Shareholders

BLRX

MT Newswires

4 months ago

BioLineRx Changes Ratio of ADSs to Ordinary Shares

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
BLRX

PR Newswire

4 months ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Announces $10 Million Registered Direct Offering
BLRX

PR Newswire

4 months ago

BioLineRx Announces $10 Million Registered Direct Offering

BLRX

Zacks Small Cap Research

5 months ago

BLRX: Ayrmid Assumes Commercialization Efforts

BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts
BLRX

GuruFocus.com

6 months ago

BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
BLRX

PR Newswire

6 months ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
BLRX

TipRanks

6 months ago

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
BLRX

PR Newswire

6 months ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
BLRX

PR Newswire

6 months ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
BLRX

PR Newswire

6 months ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
BLRX

PR Newswire

7 months ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
BLRX

PR Newswire

8 months ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BLRX: On Track for 60% Formulary Placement
BLRX

Zacks Small Cap Research

9 months ago

BLRX: On Track for 60% Formulary Placement

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX

PR Newswire

9 months ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
BLRX

PR Newswire

9 months ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BLRX: First Quarter 2024 Results
BLRX

Zacks Small Cap Research

a year ago

BLRX: First Quarter 2024 Results

Start Proud Opens the Market
BLRX

CNW Group

a year ago

Start Proud Opens the Market

Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it
BLRX

Associated Press Finance

a year ago

Will recreational pot go on sale soon in Ohio? Medical marijuana stores can now apply to sell it

BLRX

Business Wire

a year ago

Form 8.3 - Darktrace plc

Dow Jones Trims Losses As Yields Spike On Jobs Data; GameStop Dives
BLRX

Investor's Business Daily

a year ago

Dow Jones Trims Losses As Yields Spike On Jobs Data; GameStop Dives

May jobs reports signals Fed's soft landing: US Labor Secretary
BLRX

Yahoo Finance Video

a year ago

May jobs reports signals Fed's soft landing: US Labor Secretary

NICE to Webcast Financial Analyst and Investor Day at Interactions 2024
BLRX

Business Wire

a year ago

NICE to Webcast Financial Analyst and Investor Day at Interactions 2024

Notification of major holding in Kindred Group plc
BLRX

PR Newswire

a year ago

Notification of major holding in Kindred Group plc

BLRX

Business Wire

a year ago

Form 8.3 - DS Smith plc

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
BLRX

PR Newswire

a year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRX

PR Newswire

a year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX

PR Newswire

a year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx to Report First Quarter 2024 Results on May 28, 2024
BLRX

PR Newswire

a year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX

PR Newswire

a year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX

PR Newswire

a year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX

PR Newswire

a year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
BLRX

PR Newswire

a year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Announces $6 Million Registered Direct Offering
BLRX

PR Newswire

a year ago

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
BLRX

Insider Monkey

a year ago

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

BLRX

Zacks Small Cap Research

a year ago

BLRX: First Aphexda Sales Recognized

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
BLRX

PR Newswire

a year ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
BLRX

PR Newswire

a year ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
BLRX

PR Newswire

a year ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
BLRX

PR Newswire

a year ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BLRX: Poster Presentations
BLRX

Zacks Small Cap Research

a year ago

BLRX: Poster Presentations

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
BLRX

InvestorPlace

a year ago

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
BLRX

PR Newswire

a year ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Opthea Strengthens Team with Key Clinical and Regulatory Hires
BLRX

GlobeNewswire

a year ago

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Rhinebeck Bancorp, Inc. Reports Results for the Quarter and Year Ended December 31, 2023
BLRX

ACCESSWIRE

a year ago

Rhinebeck Bancorp, Inc. Reports Results for the Quarter and Year Ended December 31, 2023

BLRX

Associated Press Finance

a year ago

BCB Bancorp: Q4 Earnings Snapshot

BCB Bancorp, Inc. Earns $6.1 Million in Fourth Quarter 2023; Reports $0.35 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share
BLRX

GlobeNewswire

a year ago

BCB Bancorp, Inc. Earns $6.1 Million in Fourth Quarter 2023; Reports $0.35 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share

JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA
BLRX

PR Newswire

a year ago

JOHN HANCOCK CLOSED-END FUNDS RELEASE EARNINGS DATA

Virco Manufacturing Corporation (VIRC) Hits Fresh High: Is There Still Room to Run?
BLRX

Zacks

a year ago

Virco Manufacturing Corporation (VIRC) Hits Fresh High: Is There Still Room to Run?

Loop Industries Announces MOU For US$66 Million of Non-Dilutive Financing from Reed Management, as Part of a Joint Venture for European Infinite Loop(TM) Technology Roll-Out
BLRX

ACCESSWIRE

a year ago

Loop Industries Announces MOU For US$66 Million of Non-Dilutive Financing from Reed Management, as Part of a Joint Venture for European Infinite Loop(TM) Technology Roll-Out

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
BLRX

GlobeNewswire

a year ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now
BLRX

Simply Wall St.

a year ago

Shareholders May Be More Conservative With Northern Technologies International Corporation's (NASDAQ:NTIC) CEO Compensation For Now

Calculating The Intrinsic Value Of El Pollo Loco Holdings, Inc. (NASDAQ:LOCO)
BLRX

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of El Pollo Loco Holdings, Inc. (NASDAQ:LOCO)

Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet
BLRX

Zacks

a year ago

Wall Street Analysts Think MediWound (MDWD) Could Surge 134.77%: Read This Before Placing a Bet

Roadzen Appoints Jean-Noël Gallardo as Global Chief Financial Officer
BLRX

GlobeNewswire

a year ago

Roadzen Appoints Jean-Noël Gallardo as Global Chief Financial Officer

Oatly Announces Nationwide Availability at The Coffee Bean & Tea Leaf®
BLRX

GlobeNewswire

a year ago

Oatly Announces Nationwide Availability at The Coffee Bean & Tea Leaf®

Zacks.com featured highlights include EMCOR Group, Arcos Dorados, Photronics and Civeo
BLRX

Zacks

a year ago

Zacks.com featured highlights include EMCOR Group, Arcos Dorados, Photronics and Civeo

Calculating The Intrinsic Value Of The Cato Corporation (NYSE:CATO)
BLRX

Simply Wall St.

a year ago

Calculating The Intrinsic Value Of The Cato Corporation (NYSE:CATO)

4 Stocks Riding High on Increasing Cash Flow to Buy Now
BLRX

Zacks

a year ago

4 Stocks Riding High on Increasing Cash Flow to Buy Now

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
BLRX

PR Newswire

a year ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Terphane is Awarded GREAT PLACE TO WORK "Best Place to Work - Industry" in Brazil For Fourth Consecutive Year
BLRX

Business Wire

a year ago

Terphane is Awarded GREAT PLACE TO WORK "Best Place to Work - Industry" in Brazil For Fourth Consecutive Year

Conn’s, Inc. Announces Transformative Transaction with W.S. Badcock LLC
BLRX

GlobeNewswire

a year ago

Conn’s, Inc. Announces Transformative Transaction with W.S. Badcock LLC

BLRX

PR Newswire

a year ago

CROSS TIMBERS ROYALTY TRUST DECLARES DECEMBER CASH DISTRIBUTION

Largo Provides Update on the Ongoing Exploration Program Surrounding its Maracás Menchen Mine in Brazil
BLRX

Business Wire

a year ago

Largo Provides Update on the Ongoing Exploration Program Surrounding its Maracás Menchen Mine in Brazil

Smith-Midland Receives $3.8M J-J Hooks Barrier Rental Contract for I-64 in Virginia
BLRX

ACCESSWIRE

a year ago

Smith-Midland Receives $3.8M J-J Hooks Barrier Rental Contract for I-64 in Virginia

eHealth, Inc.'s (NASDAQ:EHTH) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week
BLRX

Simply Wall St.

a year ago

eHealth, Inc.'s (NASDAQ:EHTH) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Charles Rowland Bought 179% More Shares In Generation Bio
BLRX

Simply Wall St.

a year ago

Charles Rowland Bought 179% More Shares In Generation Bio

Investors in Largo (TSE:LGO) have unfortunately lost 90% over the last five years
BLRX

Simply Wall St.

a year ago

Investors in Largo (TSE:LGO) have unfortunately lost 90% over the last five years

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week
BLRX

Simply Wall St.

a year ago

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week

TrueCar, Inc. (NASDAQ:TRUE) is a favorite amongst institutional investors who own 51%
BLRX

Simply Wall St.

a year ago

TrueCar, Inc. (NASDAQ:TRUE) is a favorite amongst institutional investors who own 51%

Central Garden & Pet (CENT) Displays Solid Prospects Amid Risks
BLRX

Zacks

a year ago

Central Garden & Pet (CENT) Displays Solid Prospects Amid Risks

Implied Volatility Surging for On trivago (TRVG) Stock Options
BLRX

Zacks

a year ago

Implied Volatility Surging for On trivago (TRVG) Stock Options

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript
BLRX

Insider Monkey

a year ago

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call Transcript

BLRX: A Series of Fortunate Events
BLRX

Zacks Small Cap Research

a year ago

BLRX: A Series of Fortunate Events

‘Riding the Clean Energy Wave’: This Analyst Suggests 2 Stocks to Play the Renewable Energy Transition
BLRX

TipRanks

a year ago

‘Riding the Clean Energy Wave’: This Analyst Suggests 2 Stocks to Play the Renewable Energy Transition

BLRX

PR Newswire

a year ago

BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

BLRX

PR Newswire

a year ago

CROSS TIMBERS ROYALTY TRUST DECLARES NOVEMBER CASH DISTRIBUTION

Amplify Energy Insiders Added US$616.8k Of Stock To Their Holdings
BLRX

Simply Wall St.

a year ago

Amplify Energy Insiders Added US$616.8k Of Stock To Their Holdings

BLRX

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Acumen Pharmaceuticals Inc Earnings Call

BLRX

Associated Press Finance

2 years ago

Cross Timbers: Q3 Earnings Snapshot

Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates
BLRX

GuruFocus.com

2 years ago

Sutro Biopharma Inc (STRO) Reports Q3 2023 Financial Results and Business Updates

BLRX

GuruFocus.com

2 years ago

Acumen Pharmaceuticals Inc (ABOS) Reports Q3 2023 Financial Results and Provides Business Update

Ascent Industries Co. (NASDAQ:ACNT) Q3 2023 Earnings Call Transcript
BLRX

Insider Monkey

2 years ago

Ascent Industries Co. (NASDAQ:ACNT) Q3 2023 Earnings Call Transcript

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
BLRX

PR Newswire

2 years ago

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
BLRX

PR Newswire

2 years ago

BioLineRx to Report Third Quarter 2023 Results on November 20, 2023

374Water Releases Q3 2023 Results
BLRX

ACCESSWIRE

2 years ago

374Water Releases Q3 2023 Results

TAT Technologies' (NASDAQ:TATT) Returns On Capital Are Heading Higher
BLRX

Simply Wall St.

2 years ago

TAT Technologies' (NASDAQ:TATT) Returns On Capital Are Heading Higher

Share on Social Networks: